Valuation: Resverlogix Corp.

Market Cap 2.18Cr 1.53Cr 1.34Cr 1.24Cr 1.15Cr 146.35Cr 2.21Cr 15Cr 5.77Cr 72Cr 5.76Cr 5.64Cr 249.07Cr P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 11Cr 7.57Cr 6.63Cr 6.1Cr 5.67Cr 721.88Cr 11Cr 73Cr 28Cr 354.34Cr 28Cr 28Cr 1.23TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.39%
Yield 2024 *
-
Yield 2025 -
1 week-5.26%
1 month-10.00%
3 months-18.18%
6 months-5.26%
Current year-10.00%
1 week 0.09
Extreme 0.09
0.1
1 month 0.09
Extreme 0.09
0.1
Current year 0.08
Extreme 0.085
0.14
1 year 0.04
Extreme 0.045
0.3
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap.
04/05Option

Chief Financial Officer

3,00,000 0.0949%
04/05Option

Chief Financial Officer

3,00,000 0.0949%
06/03Option

Chief Financial Officer

62,500 0.0217%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.26%+80.00%-14.29% 2.18Cr
-2.14%+3.51%+74.50%+131.10% 5.91TCr
-0.93%+4.05%+73.64%+90.53% 5.52TCr
-2.78%+0.36%-14.04%-10.56% 2.47TCr
+0.49%+6.89%+15.48%+453.41% 2.42TCr
+0.64%+14.41%+44.27%-3.20% 1.97TCr
-2.19%+6.34%+39.72%-29.60% 1.76TCr
+3.58%+25.11%+196.41%+363.46% 1.62TCr
+4.91%+25.24%+44.61% - 1.48TCr
-0.84%+2.43%+25.91%+187.64% 1.4TCr
Average +0.06%+7.02%+58.05%+129.83% 2.46TCr
Weighted average by Cap. -0.59%+6.43%+58.15%+136.11%

Financials

2024 2025
Net sales - -
Net income -76.35L -53.7L -47.03L -43.32L -40.21L -51Cr -77.38L -5.18Cr -2.02Cr -25Cr -2.02Cr -1.97Cr -87Cr -77.67L -54.63L -47.84L -44.06L -40.9L -52Cr -78.72L -5.27Cr -2.05Cr -26Cr -2.05Cr -2.01Cr -89Cr
Net Debt 8.19Cr 5.76Cr 5.04Cr 4.64Cr 4.31Cr 549.24Cr 8.3Cr 56Cr 22Cr 269.6Cr 22Cr 21Cr 934.74Cr 8.58Cr 6.03Cr 5.28Cr 4.87Cr 4.52Cr 575.53Cr 8.7Cr 58Cr 23Cr 282.51Cr 23Cr 22Cr 979.49Cr
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
06/26/06 CA$0.0900 0.00% 23,500
02/26/02 CA$0.0900 0.00% 15,997
30/26/30 CA$0.0900 -5.26% 2,20,500
29/26/29 CA$0.0950 +5.56% 6,331